A phase I/II study of fixed-dose-rate gemcitabine and S-1 with concurrent radiotherapy for locally advanced pancreatic cancer

作者：Goji Takahiro; Kimura Tetsuo; Miyamoto Hiroshi; Takehara Masanori; Kagemoto Kaizo; Okada Yasuyuki; Okazaki Jun; Takaoka Yoshifumi; Miyamoto Yoshihiko; Mitsui Yasuhiro; Matsumoto Sayo; Sueuchi Tatsuhisa; Tanaka Kumiko; Fujino Yasuteru; Takaoka Toshi; Kitamura Shinji; Okamoto Koichi; Kimura Masako; Sogabe Masahiro; Muguruma Naoki; Okahisa Toshiya; Sato Yasuhiro; Sagawa Tamotsu; Fujikawa Koji; Sato Yasushi; Ikushima Hitoshi; Takayama Tetsuji^*

来源：Cancer Chemotherapy and Pharmacology, 2015, 76(3): 615-620.

DOI：10.1007/s00280-015-2835-3

• Pancreatic cancer
• Gemcitabine
• S-1
• Chemoradiotherapy
• Radiosensitizer

This study was conducted to identify the maximum-tolerated dose (MTD) of fixed-dose-rate gemcitabine (FDR-gem) administered concurrently with S-1 and radical radiation for locally advanced pancreatic cancer (LAPC) and to provide efficacy and safety data.
Patients with unrespectable pancreatic cancer confined to the pancreatic region were treated with FDR-gem (300-400 mg/m(2), 5 mg/m(2)/min) on days 1, 8, 22, and 29 and 60 mg/m(2) of S-1 orally on days 1-14, 22-35. A total radiation dose of 50.4 Gy (1.8 Gy/day, 28 fractions) was delivered concurrently.
Twenty-five patients were enrolled; all were evaluable for toxicity assessment. In phase I, eight patients were treated in sequential cohorts of three to five patients per dose level. The MTD was reached at level 2, and dose-limiting toxicities were neutropenia and thrombocytopenia. The recommended doses were 300 mg/m(2) of gemcitabine and 60 mg/m(2) of S-1 daily. The overall response rate was 25 % and disease control rate (partial response plus stable disease) was 92 %. The progression-free survival was 11.0 months. The median overall survival and 1-year survival rates were 16.0 months and 73 %, respectively.
The combination of FDR-gem and S-1 with radiation is a feasible regimen that shows favorable antitumor activity with an acceptable safety profile in patients with LAPC.

• 出版日期2015-9